Increases in Antihypertensive Prescriptions and Reductions in Cardiovascular Events in Canada

Hypertension

Volumn 53, Issue 2, 2009, Pages 128-134

  Campbell, Norm R C ^a   Brant, Rollin ^b   Johansen, Helen ^c   Walker, Robin L ^d   Wielgosz, Andreas ^e   Onysko, Jay ^d   Gao, Ru Nie ^d   Sambell, Christie ^c   Phillips, Stephen ^f   McAlister, Finlay A ^g  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c STATISTICS CANADA   (Canada)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^e UNIVERSITY OF OTTAWA   (Canada)

^f DALHOUSIE UNIVERSITY   (Canada)

^g UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antihypertensive treatment; Clinical practice guideline; Epidemiology; Heart failure; Hypertension; Myocardial infarction; Stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT; PRESCRIPTION DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DISEASE ASSOCIATION; EDUCATION PROGRAM; HEALTH CARE; HEALTH CARE ORGANIZATION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MORTALITY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; STROKE; TIME SERIES ANALYSIS; VOCATIONAL EDUCATION; FEMALE; HEALTH SURVEY; HEART INFARCTION; INCIDENCE; MALE; MIDDLE AGED; PUBLIC HEALTH; RISK FACTOR; STATISTICS; WORLD HEALTH ORGANIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CANADA; CARDIOVASCULAR DISEASES; FEMALE; HEALTH SURVEYS; HEART FAILURE; HOSPITALIZATION; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NATIONAL HEALTH PROGRAMS; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTION DRUGS; PUBLIC HEALTH; RISK FACTORS; STROKE; WORLD HEALTH ORGANIZATION;

EID: 59849090727     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.119784     Document Type: Article

References (48)

1. Rodgers A, Vaughan P, Prentice T, Edejer TT-T, Evans D. The World Health Report 2002. Geneva, Switzerland: World Health Organization; 2002.
2. Turnbull F, Neal B, Algert C, Chalmers J, Woodward M, MacMahon S. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527-1535.
3. Collins R, Peto R, MacMahon S, Hebert P, Fiebert NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
4. Lindholm L, Ejlertsson G, Schersten B. High risk of cerebro-cardiovas- cular morbidity in well treated male hypertensives. Acta Med Scand. 1984;216:251-259.
5. Clausen J, Jensen G. Blood pressure and mortality: an epidemiological survey with 10 years follow-up. J Hum Hypertens. 1992;6:53-59.
6. Merlo J, Ranstam J, Liedholm H, Hedblad B, Lindberg G, Lindblad U, Isacsson S-O, Melander A, Rastam L. Incidence of myocardial infarction in elderly men being treated with antihypertensive drugs: population based cohort study. BMJ. 1996;313:457-461.
7. Thurmer HL, Lund-Larsen PG, Tverdal A. Is blood pressure treatment as effective in a population setting as in controlled trials? Results from a prospective study. J Hypertens. 1994;12:481-490.
8. Tunstall-Pedoe H, Connaghan J, Woodward M, Tolonen H, Kuulasmaa K. Pattern of declining blood pressure across replicate population surveys of the WHO MONICA project, mid-1980s to mid-1990s, and the role of medication. BMJ. 2006;332:629-635.
9. Lenfant C. Reflections on hypertension control rates. A message from the director of the National Heart, Lung, and Blood Institute. Arch Intern Med. 2002;162:131-132.
10. Primatesta P, Poulter NR. Improvement in hypertension management in England: results from the Health Survey for England 2003. J Hypertens. 2006;24:1193-1200.
11. Karppanen H, Mervaala E. Sodium intake and hypertension. Prog Cardiovasc Dis. 2006;49:59-75.
12. McAlister FA. The Canadian Hypertension Education Program-a unique Canadian initiative. Can J Cardiol. 2006;22:559-564.
13. Drouin D, Campbell NR, Kaczorowski J. Implementation of recommendations on hypertension: the Canadian Hypertension Education Program. Can J Cardiol. 2006;22:595-598.
14. Campbell NR, Onysko J. The Outcomes Research Task Force and the Canadian Hypertension Education Program. Can J Cardiol. 2006;22: 556-558.
15. Onysko J, Maxwell C, Eliasziw M, Zhang J, Johansen H, Campbell N. Large increases in hypertension diagnosis and treatment in Canada following a health care professional education program. Hypertension. 2006; 48:853-860.
16. Campbell NRC, McAlister FA, Brant R, Levine M, Drouin D, Feldman R, Herman R, Zarnke K. Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Program. J Hypertens. 2003;21:1591-1597.
17. Campbell NRC, Tu K, Brant R, Duong-Hua M, McAlister FA. The impact of the Canadian Hypertension Education Program on antihypertensive prescribing trends. Hypertension. 2006;47:22-28.
18. Leenen F, Dumais J, Mclnnis N, Turton P, Stratychuk L, Nemeth K, Lum-Kwong MM, Fodor G. 2006 Ontario Survey on the Prevalence and Control of Hypertension (ON-BP). CMAJ. 2008;178:1441-1449.
19. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, Ninth Revision. Geneva, Switzerland: World Health Organization; 1977.
20. World Health Organization. International Statistical Classification of Diseases and Related Health Problems, Tenth Revision. Geneva, Switzerland: World Health Organization; 2002.
21. Quan H, Sundarararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, Saunders D, Beck C, Feasby T, Ghali W. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130-1139.
22. Quan H, Li B, Saunders D, Parsons GA, Nilsson C, Alibhai A, Ghali WA. Assessing validity of ICD-9-CM and ICD-10 administrative data in recording clinical conditions in a unique dually-coded database. Health Serv Res. 2008;43:1424-1441.
23. Tambay JL, Catlin G. Sample design of the National Population Health Survey. Health Reports. 1995;7:29-38.
24. Beland Y. Canadian Community Health Survey-methodological overview. Health Reports. 2002;13:9-14.
25. The World Heart Federation. Impending Global Pandemic of Cardiovascular Diseases. Barcelona, Spain: Prous Science; 1999.
26. US Department of Health and Human Services. A Public Health Action Plan to Prevent Heart Disease and Stroke. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2003.
27. The Changing Face of Heart Disease and Stroke in Canada 2000. Ottawa, Ontario, Canada: Heart and Stroke Foundation of Canada; 1999.
28. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng Z-J, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-el51.
29. Johansen H, Thillaiampalam S, Nguyen D, Sambell C. Diseases of the circulatory system-hospitalization and mortality. Health Reports. 2005; 17:49-53.
30. Manuel DG, Leung M, Nguyen K, Tanuseputro P, Johansen H. Burden of cardiovascular disease in Canada. Can J Cardiol. 2003;19:997-1004.
31. Lenfant C, Roccella EJ. Preventing strokes: considerations for developing health policy. Health Reports. 1994;6:216-223.
32. Hunink MGM, Goldman L, Tosteson ANA, Mittleman MA, Goldman PA, Williams LW, Tsevat J, Weinstein MC. The recent decline in mor-tality from coronary heart disease, 1980-1990-the effect of secular trends in risk factors and treatment. JAMA. 1997;277:535-542.
33. Klungel OH, Stricker BHC, Breteler MMB, Seidell JC, Psaty BM, de Boer A. Is drug treatment of hypertension in clinical practice as effective as in randomized controlled trials with regard to the reduction of the incidence of stroke? Epidemiology. 2001;12:339-344.
34. Bonita R, Beaglehole R. Increased treatment of hypertension does not explain the decline in stroke mortality in the United States, 1970-1980. Hypertension. 1989;13:169-173.
35. Statistics Canada. Health Indicators. Ottawa, Canada: Canadian Government Publishing, Public Works and Government Services Canada; 2001.
36. Statistics Canada. Health Indicators. Ottawa, Canada: Canadian Government Publishing, Public Works and Government Services Canada; 2005.
37. Statistics Canada. Health Indicators. Ottawa, Canada: Canadian Government Publishing, Public Works and Government Services Canada; 2002.
38. Statistics Canada. Health Indicators. Ottawa, Canada: Canadian Government Publishing, Public Works and Government Services Canada; 2004.
39. Jackevicius CA, Tu K, Filate WA, Brien SE, Tu JV. Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001. Can J Cardiol. 2003;19:1359-1366.
40. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-952.
41. Sacco RL. Risk factors and outcomes for ischemic stroke. Neurology. 1995;45:S10-S14.
42. Jeremias A, Gibson M. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142:786-791.
43. French J, White H. Clinical implications of the new definition of myocardial infarction. Heart. 2004;90:99-106.
44. Jahari DV, Hoybook K. Retrospective database review for use of cardiac troponin 1 for detection of myocardial infarction. Clin Chem. 2001; 47:A212.
45. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense H-W, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F. Hypertension prevalence and blood pressure levels in 6 European Countries, Canada, and the United States. JAMA. 2003;289:2363-2369.
46. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22: 11-19.
47. Doran T, Fullwood C, Gravelle H, Reeves D, Kontopantelis E, Hiroeh U, Roland M. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med. 2006;355:375-384.
48. Hemmelgam BR, Chen G, Walker R, McAlister FA, Quan H, Tu K, Khan N, Campbell N. Trends in antihypertensive drug prescriptions and physician visits in Canada between 1996 and 2006. Can J Cardiol. 2008;24:507-512.